UroGen Pharma Reports Strong Long-Term Results for Bladder Cancer Treatment ZUSDURI

Key Facts

1The Journal of Urology published the ENVISION trial results for UroGen Pharma's ZUSDURI.

2The drug achieved a 79.6% complete response rate at 3 months.

3Kaplan-Meier analysis showed a 72.2% probability of remaining event-free at 24 months.

UroGen Pharma Ltd. (URGN) announced the publication of Phase 3 ENVISION trial results for its bladder cancer treatment, ZUSDURI (UGN-102). The findings, published in The Journal of Urology, highlight a significant 79.6% complete response rate within the first three months of treatment. Long-term data from the Kaplan-Meier analysis indicated a 72.2% probability of patients remaining event-free at the 24-month mark. This durability of response is a critical milestone for the company as it seeks regulatory approval for the drug in treating low-grade non-muscle invasive bladder cancer (NMIBC). The peer-reviewed publication validates the clinical efficacy of ZUSDURI, potentially positioning it as a leading non-surgical alternative. Analysts view these results as a positive catalyst for the stock, reinforcing its competitive profile in the oncology market.